Abstract:The majority of current cancer immunotherapy strategies target and potentiate antitumor adaptive immune responses. Unfortunately, the efficacy of these treatments has been limited to a fraction of patients within a subset of tumor types, with an aggregate response rate of approximately 20% to date across all malignancies. The success of therapeutic inhibition of programmed death protein 1 (PD-1), protein death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with immune checkpoint inhibitors (ICI) has been limited to “hot” tumors characterized by preexisting T cell infiltration, whereas “cold” tumors, which lack T cell infiltration, have not achieved durable benefit. There are several mechanisms by which “cold” tumors fail to generate spontaneous immune infiltration, which converge upon the generation of an immunosuppressive tumor microenvironment (TME). The role of the innate immune system in tumor immunosurveillance and generation of antitumor immune responses has been long recognized. In recent years, novel strategies to target innate immunity in cancer therapy have emerged, including therapeutic stimulation of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs); the DNA sensing cGAS/STING pathway; nucleotide-binding oligomerization domain-like receptors (NLRs), such as NLRP3; and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs). In addition, therapeutic modulation of key innate immune cell types, such as macrophages and natural killer cells, has been investigated. Herein, we review therapeutic approaches to activate innate immunity within the TME to enhance antitumor immune responses, with the goal of disease eradication in “cold” tumors. In addition, we discuss rational immune-oncology combination strategies that activate both innate and adaptive immunity, with the potential to enhance the efficacy of current immunotherapeutic approaches.

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy

The Therapeutic Value of Targeting Inflammation in Gastrointestinal Cancers

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Targeting Innate Immunity in Cancer Therapy

Inflammation and cancer: advances and new agents

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Tumor-associated myeloid cells: diversity and therapeutic targeting

Inflammation and tumor progression: signaling pathways and targeted intervention

Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Anti-Inflammatory Drugs as Anticancer Agents

Immune cell networking in solid tumors: focus on macrophages and neutrophils

Exploiting innate immunity for cancer immunotherapy

Macrophages as tools and targets in cancer therapy

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Tumour-associated macrophages as treatment targets in oncology

Innate Immunity and Cancer Pathophysiology.

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy